Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted Fast ...

Please provide your email address to receive an email when new articles are posted on . All eyes that received a single-layer graft and a 24-hour pressure patch showed complete healing. A three-layer ...

Please provide your email address to receive an email when new articles are posted on . EyeGate Pharmaceuticals' Ocular Bandage Gel demonstrated potential for use in treating corneal epithelial ...

-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no ...

-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing, ...

SAN DIEGO, August 18, 2023 (Newswire.com) - Amber Ophthalmics, Inc. (Amber), a privately held, clinical stage biopharmaceutical company, announced today that Dr. Mark S. Gorovoy from Gorovoy M.D. Eye ...

-- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results-- The CHASE Phase 2b trial is a multicenter, ...

-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated ...

Corneal defects often heal themselves, but serious injuries that are left untreated can result in inflammation, infection, ulceration and even blindness. A new study provides exciting evidence ...

Corneal defects often heal themselves, but serious injuries that are left untreated can result in inflammation, infection, ulceration and even blindness. A new study provides exciting evidence ...